Our data demonstrate that TNFR1 inhibition through Atrosimab administration efficiently blocked TNFR1-mediated inflammatory responses in a model of acute TNF-mediated inflammation and in experimental arthritis, NASH and EAE. Here, TNF is linked to arthritic joint disease.